US spot XRP ETFs recorded US$13.59 million (AU$20.7 million) of net inflows on Jan. 2, lifting cumulative inflows since launch to about US$1.18 billion (AU$1.8 US spot XRP ETFs recorded US$13.59 million (AU$20.7 million) of net inflows on Jan. 2, lifting cumulative inflows since launch to about US$1.18 billion (AU$1.8

XRP Breaks $2 as ETF Inflows Fuel Early-2026 Rally

2026/01/05 13:03
2 min read
For feedback or concerns regarding this content, please contact us at [email protected]
  • XRP rose to $2.11 and became the fourth-largest cryptocurrency by market cap, fueled by $13.59 million in net ETF inflows on January 2.
  • While broader crypto markets and Bitcoin funds remained flat, spot XRP ETFs reached a cumulative inflow total of approximately $1.18 billion.
  • The price surge is linked to the departure of SEC Commissioner Caroline Crenshaw and anticipation of a Market Structure Bill markup on January 15.

US spot XRP ETFs recorded US$13.59 million (AU$20.7 million) of net inflows on Jan. 2, lifting cumulative inflows since launch to about US$1.18 billion (AU$1.8 billion), according to data cited by SoSoValue. Traders said the ongoing buying has supported XRP in early 2026, even as broader crypto markets have been relatively flat.

XRP moved above US$2 (AU$2.9) on Friday for the first time since mid-December, with market participants pointing to the combination of ETF demand and shifting expectations around US regulation.

Total XRP Spot ETF Net Inflow. Source: SoSo Value.

By this Monday morning, XRP trades at US$2.11 (AU$3.16), a 12% increase in the last seven days, and one of the best performers this Monday with a surge of over 5%, dethroning Binance Coin (BNB) from the fourth place as the largest crypto asset by market cap.

Source: TradingView.

Related: Crypto Hack Losses Plunge 60% in December Despite $50M Address Poisoning Scam

A Friendlier SEC?

Part of XRP’s price shift is tied to the departure of SEC Commissioner Caroline Crenshaw. Some traders viewed her exit as reducing resistance to more crypto-friendly policy decisions. Crenshaw had been a prominent critic of spot crypto ETFs and, according to market commentary, opposed the SEC dropping its appeal in the Ripple case.

Policy speculation also contributed to sentiment and traders highlighted a possible markup of a Market Structure Bill on Jan. 15, keeping expectations elevated into the first quarter and helping XRP outperform.

Flows into other major crypto ETF products were described as less supportive over the same period, with weaker demand for Bitcoin funds cited by analysts. That divergence reinforced the view that XRP’s move has been driven mainly by XRP-specific catalysts rather than a broad risk-on push across crypto.

Read more: Beckham-Backed Prenetics Drops Bitcoin Treasury Plans After $48M Raise

The post XRP Breaks $2 as ETF Inflows Fuel Early-2026 Rally appeared first on Crypto News Australia.

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3668
$1.3668$1.3668
+0.75%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09